Alector (NASDAQ:ALEC) is a clinical-stage biotechnology company dedicated to discovering and developing immuno-neurology therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform focuses on harnessing the innate immune system to address the underlying causes of disorders such as Alzheimer’s disease, frontotemporal dementia (FTD), and progressive multiple sclerosis (MS). By targeting key immune pathways in the brain, Alector aims to modulate microglial and macrophage function to clear toxic proteins and restore neuronal health.
The company’s pipeline features several lead programs, including AL001, an antibody designed to correct progranulin deficiencies in patients with FTD, and AL002, which targets the TREM2 receptor to enhance microglial response. Additional candidates address protein aggregation and inflammatory processes, positioning Alector at the forefront of immune-based approaches to neurodegeneration. Each program is progressing through clinical or preclinical development, with an emphasis on robust biomarker strategies to demonstrate mechanism of action and disease modification.
Founded in 2013 by Dr. Arnon Rosenthal and a team of immunologists and neuroscientists, Alector has built collaborative relationships with academic institutions and strategic partners to accelerate its research efforts. The company completed its initial public offering in 2018 and has since advanced multiple clinical trials across North America and Europe. Partnerships with leading pharmaceutical firms and research consortia have expanded access to novel targets and bolstered translational capabilities.
Headquartered in South San Francisco, with research operations in Cambridge, U.K., Alector benefits from proximity to major biotech hubs. Under the leadership of Dr. Arnon Rosenthal as President and CEO, alongside a seasoned executive team with deep experience in drug development, the company continues to build on its mission to translate cutting-edge science into therapies that address the unmet needs of patients suffering from debilitating neurodegenerative conditions.
